The QualityStocks Daily Tuesday, June 11th, 2019

Today's Top 3 Investment Newsletters

PoliticsAndMyPortfolio (SEII) +60.00%

QualityStocks (NMEX) +46.63%

StockMarketWatch (JAGX) +35.92%

The QualityStocks Daily Stock List

Ferguson plc (FERGY)

StockTwits, Zacks, TipRanks, 4-Traders, Capital Cube, Stockwatch, Trading View, Stockhouse, Morningstar, and Wallmine reported earlier on Ferguson plc (FERGY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Ferguson plc distributes plumbing and heating products in the U.S.A., the UK, Canada, and Central Europe. The Company is the world’s leading specialist distributor of plumbing and heating products. Ferguson operates a network of 2,280 branches and 19 distribution centers. The Company is based in Wokingham, UK and its shares trade on the OTC Markets Group’s OTCQX.

Ferguson mainly serves the Repair, Maintenance and Improvement (RMI) markets. The Company holds leading positions in many of these markets. Ferguson bridges the gap between the large supplier base and geographically dispersed professional customers. The Company has 5,900 Fleet vehicles and more than 1 Million customers.

Ferguson has large scale distribution, branch and showroom networks to ensure customer supply. The Company holds leading positions in the UK, Canada and Central Europe with local customer relationships supported by way of an industry leading supply chain, superior technology and national scale.

The UK operates two businesses under the Wolseley brand serving the trade market through 567 branches served by six distribution centers. Branches provide same day and next day product availability. The UK business chiefly serves RMI markets. It has relatively low exposure to the new residential construction market.

Canada and Central Europe operates across two nations, Canada and the Netherlands. Wolseley Canada serves the residential, commercial, as well as industrial sectors in RMI and new construction. Wasco in the Netherlands operates in the residential RMI and residential new-construction markets. Both businesses mainly serve trade customers. The businesses operate 265 branches with three distribution centers. In October of 2018, Ferguson announced its intention to dispose of the Wasco business.

Ferguson also distributes pipes, valves, fittings, hydrants, meters, and related water management products. It also offers related services, such as water line tapping and pipe fusion services. The Company also distributes heating, ventilation, air conditioning, refrigeration equipment, and parts and supplies to specialist contractors in the residential and commercial markets for repair and replacement; and PVF products to industrial customers.

Ferguson also fabricates and supplies fire protection systems and bespoke fabrication services to commercial contractors for new construction and renovation projects. It also offers products, services, and solutions to enable maintenance of facilities across different RMI markets and offers supply chain management solutions for PVF; and industrial maintenance, repair, and operations specializing in delivering automation, instrumentation, engineered products, and turn-key solutions.

Ferguson also sells its home improvement products and operates its B2B business mainly under the Ferguson brand. Ferguson also provides products and services for the maintenance of multi-family properties, government agencies, hospitality, education, healthcare, and other facilities.

Ferguson plc (FERGY), closed Tuesday's trading session at $6.52, up 1.88%, on 136,997 volume with 476 trades. The average volume for the last 3 months is 94,919 and the stock's 52-week low/high is $5.95/$8.67.

chart

Artelo Biosciences, Inc. (ARTL)

NetworkNewsWire, StockPulse, Momentous News, Market Exclusive, Stockwatch, Trading View, Proactive Investors, Simply Wall St, and Stockhouse reported earlier on Artelo Biosciences, Inc. (ARTL), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Established in 2011, Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company based in La Jolla, California. The Company focuses on the development of therapeutics that modulate the endocannabinoid system. It is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions. These include cancer, pain, as well as inflammation. The Company previously went by the name Reactive Medical, Inc. It changed its name to Artelo Biosciences, Inc. in April of 2017.

Artelo Biosciences’ belief is that a biopharma approach will lead to novel and high-impact therapeutics that harness the full potential of the endocannabinoid system (ECS). The endocannabinoid system (ECS) is a widespread neuromodulatory system. It plays a vital role in human central nervous system (CNS) development, synaptic plasticity, and the response to endogenous and environmental insults.

The Company’s business model is to develop multiple pharmacological approaches to ECS modulation. Candidate therapeutic compounds within Artelo’s present portfolio are based on targeting cannabinoid receptors and endocannabinoid transport inhibition.

The Company’s pipeline encompasses numerous mechanisms for endocannabinoid system modulation. Specific programs now in development include ART27.13 – a high-potency GPCR Agonist (anorexia, cancer). Programs in development also include ART12.11 - proprietary cocrystal (multiple indications), and ART26.12 – a FABP5 Inhibitor (cancer, pain).

Two of Artelo Biosciences’ development programs were licensed from established and respected organizations. These organizations have already conducted pre-clinical research and, in some cases, clinical research. Artelo’s science and regulatory teams are taking advantage of this research to hasten development and commercialization timelines across the Company’s growing portfolio. Artelo Biosciences applies innovative scientific, regulatory, and commercial discipline to develop high-impact therapies.

In October 2018, Artelo Biosciences announced positive preclinical results with its product candidate, ART27.13, a clinic-ready, potent, peripherally restricted CB1/CB2 synthetic agonist with a target indication in cancer-related anorexia and weight loss. ART27.13 demonstrated in-vitro anti-proliferative activity in cancer cell line cultures.

The results are alike to activity shown by other cannabinoid compounds. The Company stated that the results are encouraging to the continued evaluation of ART27.13 as a potential anti-cancer agent, in addition to its expected role in treating anorexia. Artelo is also continuing clinical study-enabling activities for ART27.13 for a Phase 1b/2a study in cancer-related anorexia planned to start this year.

Artelo Biosciences, Inc. (ARTL), closed Tuesday's trading session at $0.99, down 10.00%, on 23,000 volume with 13 trades. The average volume for the last 3 months is 935 and the stock's 52-week low/high is $0.27/$1.75.

chart

Valens GroWorks Corp. (VGWCF)

Micro Small Cap, Micro Cap Daily, Stockwatch, Profit Confidential, NIC Investors, Midas Letter, Insider Financial, MarketWatch, Investing News, InvestorsHub, New Cannabis Ventures, Proactive Investors, and Stockhouse reported previously on Valens GroWorks Corp. (VGWCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Valens GroWorks Corp. is a multi-licensed, vertically integrated provider of cannabis products and services. It concentrates on diverse proprietary extraction methodologies, distillation, cannabinoid isolation and purification, and associated quality testing. The Company cultivates and creates first-rate cannabis extracts in the Okanagan Valley of British Columbia (BC). OTCQB-listed, Valens GroWorks is headquartered in Kelowna, BC.

Valens GroWorks ensures that it is in full control at every step of the process. It transforms cannabis plants into supreme oils for local and global markets. Valens industry leading extraction techniques are used to create oils for a variety of cannabis producers and a versatile range of cannabis products. Valens is the first company in Canada to be ISO 17025 accredited for cannabis testing. This is the international gold standard.

Valens is Health Canada licensed extracting for cannabis oils, edibles, topicals and more. Its Extraction Services include Crude Oil, Refined Oil, and also white labelling. The Company’s leading-edge research and analysis facility is called the “Centre of Excellence in Plant-Based Science” by Thermo Fisher.

Valens GroWorks announced this past April that it entered into an arm's length binding multi-year extraction services agreement to provide cannabis and hemp extraction services to HEXO Corp. HEXO is a foremost cannabis producer and consumer packaged goods (CPG) cannabis company.

HEXO will supply Valens GroWorks with an annual minimum of 30,000kg in the first year and 50,000kg in the second year of cannabis and hemp biomass. Valens will process this material on a fee for service basis into premium quality resins and distillates using its leading proprietary extraction processing methods.

Valens GroWorks also announced in April that it is the first third party cannabis extraction company in Canada to receive organic certification for cannabis oil production from Pro-Cert Organic Systems Ltd. for its proprietary CO2 and ethanol extraction processing methods in accordance with the Canadian Organic Standards. The certification gives Valens GroWorks the ability to produce certified organic cannabis oil from hemp and cannabis biomass that is organically cultivated and certified.

Furthermore, in May, Valens GroWorks announced that it entered into an arm's length binding multi-year extraction services agreement to provide cannabis extraction services to Tantalus Labs. Tantalus is a leading British-Columbia-based cannabis producer. Valens will process the cannabis biomass provided by Tantalus Labs on a fee for service basis into premium quality resins and distillates.

Yesterday, Valens GroWorks announced that it expanded the volume of extraction services and added an option to provide contract manufacturing services to the arm's length, binding multi-year agreement earlier announced February 26, 2019 with Tilray, Inc. Tilray is an international leader in cannabis research, cultivation, production and distribution.

Valens will extract on a fee for service basis a minimum annual quantity of 60,000kg of dried cannabis and hemp biomass, up 300 percent from the 15,000kg annual commitment outlined in the original agreement. Valens may also provide contract manufacturing services for tincture bottles and gel caps, with the option to offer contract manufacturing services for other product formats, including vaporizer cartridges and topicals as Health Canada regulations permit.

Valens GroWorks Corp. (VGWCF), closed Tuesday's trading session at $3.04, up 3.40%, on 177,378 volume with 286 trades. The average volume for the last 3 months is 412,588 and the stock's 52-week low/high is $0.794/$3.66.

chart

Cannabis Sativa, Inc. (CBDS)

Awesome Penny Stocks, OTC Markets, Micro Small Cap, Micro Cap Daily, Investing Daily, Green Rush Review, Stockopedia, TipRanks, Stockhouse, NIC Investors, Dividend Investor, and Stockwatch reported previously on Cannabis Sativa, Inc. (CBDS), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Cannabis Sativa, Inc. engages in the licensing of cannabis related intellectual property (IP), marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. Furthermore, the Company seeks strategic partners for the acquisition of operating companies, IP and other assets that fit within its corporate vision. OTCQB-listed, Cannabis Sativa has its corporate office in Mesquite, Nevada.

The Company licenses the "hi" and "White Rabbit" brands, and also holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, and a U.S. Patent for a marijuana lozenge. It also holds a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery and trade secret formulas and processes.

Furthermore, Cannabis Sativa offers the hi benefits discount pharmacy card, and operates different subsidiaries. These subsidiaries include PrestoDoctor(R), Wild Earth Naturals(R), and iBudtender. In addition, the Company is the official licensee for the Virgin Mary Jane Brand.

The Company’s aim is to brand and market the highest quality, legal cannabis and hemp products and to innovate. It foresees a future where the hi Brand is synonymous with the highest quality and best value in the space. hi Brands International focuses on premium CBD & THC products. Only pure sourced, all-natural ingredients go into Cannabis Sativa’s Hemp, CBD, and THC infused products.

Last week, Cannabis Sativa announced a signed Letter of Intent (LOI) to acquire Lacuna Botanicals. Lacuna is a premier Colorado based CBD product line with manufacturing and distribution. Lacuna Botanicals bioactive creams, elixirs, oils and pet care products incorporate a broad array of botanical ingredients including terpenes, essential oils and Cannabinoids such as CBD. At present, Lacuna Botanicals offers its products via upscale spas and exclusive outlets.

Cannabis Sativa President, Mr. David Tobias, said, "We are pleased to make this deal with Infinite Interactions to acquire a majority of the Lacuna Botanicals company. The Lacuna Botanicals team will continue operating from their Colorado facility which we plan to expand, and to keep ramping up sales of their current lines, while at the same time offering new, exceptional product concepts to the markets."

Cannabis Sativa, Inc. (CBDS), closed Tuesday's trading session at $1.81, up 1.69%, on 72,564 volume with 157 trades. The average volume for the last 3 months is 73,379 and the stock's 52-week low/high is $1.72/$8.50.

chart

Ionix Technology, Inc. (IINX)

OTC Markets, Simply Wall St, Open Insider, Stockhouse, Financial Content, MarketWatch, Wallet Investor, YCharts, Current Charts, Barchart, The Street, Morningstar, Small Cap Exclusive, Market Exclusive, Wallmine, Stockopedia, Last10k, and Dividend Investor reported previously on Ionix Technology, Inc. (IINX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Ionix Technology, Inc. is a business aggregator in photoelectric display and smart energy fields. The Company is concentrating on becoming the business aggregator that primarily promotes photoelectric display, smart energy and lead industrial technology development since restructuring. Through incorporating high quality enterprises and unique forward-looking technologies, Ionix provides more optimized green energy solutions. The Company previously went by the name Cambridge Projects, Inc. It changed its name to Ionix Technology, Inc. in February of 2016.

Ionix Technology has four operating subsidiaries. One is Changchun Fangguan Photoelectric Display Technology Co., Ltd. It specializes in developing, designing, producing, and selling TN and STN LCD, STN, CSTN, and TFT LCD modules and other related products. Another subsidiary is Shenzhen Baileqi Electronic Technology Co., Ltd. It specializes in LCD slicing, filling, researching and designing, manufacturing and selling of LCD Modules (LCM) and PCBs.

Subsidiary Lisite Science Technology (Shenzhen) Co., Ltd., engages in the production of intelligent electronic devices. Furthermore, subsidiary Dalian Shizhe New Energy Technology Co., Ltd., engages in photo-voltaic power generation, electric vehicles and charging piles with corresponding operation and maintenance and three-dimensional parking.

At present, Ionix has embarked on the layout of industrialization and marketization of front end materials and back end modules of flexible folding liquid crystal displays by taking Changchun Fangguan and Shenzhen Baileqi as production bases. This is to capture the market share of OLED high technology.

Ionix Technology announced in April 2019 that its subsidiary Changchun Fangguan Electronics Technology Co., Ltd. completed a capital increase of USD 5.92 Million to invest in its OLED flexible screen business. In December 2018, Ionix acquired 95.14 percent control of Changchun Fangguan and became an aggregator in the photoelectric display and smart energy fields in China. This has also laid a strong foundation for its prospective future development and technology innovation.

Recently, Ionix Technology announced its financial results for the three months ended March 31, 2019. Total Revenues increased by 146 percent from the three months ended March 31, 2018 to the three months ended March 31, 2019.

Mr. Yubao Liu, Ionix Technology’s Chief Executive Officer, said, "The financial results for the third quarter 2019 demonstrate the benefits from our recent acquisition. Our gross profit margin grew to 22 percent during the three months ended March 31, 2019 compared to 11 percent for the three months ended March 31, 2018, driven primarily by the higher gross margin from the acquired operation of Fangguan Electronics."

Ionix Technology, Inc. (IINX), closed Tuesday's trading session at $1.83, down 1.61%, on 425 volume with 3 trades. The average volume for the last 3 months is 1,967 and the stock's 52-week low/high is $1.02/$2.75.

chart

Seedo Corp. (SEDO)

OTC Markets, Street Insider, CannabisFN, Barchart, InvestorsHub, Stockap, Real Investment Advice, Stockhouse, Cash Crop Today, Green Prophet, and Stockwatch reported beforehand on Seedo Corp. (SEDO), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Seedo Corp. is an agritech company providing the world's first fully automated and controlled indoor growing machine for the "at-home agriculture" markets. The Company focuses on the development and distribution of home growing automated machines for various herbs and vegetables worldwide. Established in 2015, Seedo lists on the OTC Markets’ OTCQB and the Company is based in Israel. Seedo is backed by a group of global investors including Cannabics Pharmaceuticals.

Seedo also develops herbs and vegetables commercial containers. The Company provides growers with the freedom to cut costs while producing high yields of lab-grade, pesticide-free herbs and vegetables. Its AI-powered (Artificial Intelligence), turnkey systems enable anyone from average consumers to large-scale producers the ability to grow without prior experience or ample space.

Seedo’s hermetically sealed systems are controlled and managed by the AI software. This software analyzes the plant's development and takes actions to optimize growing parameters based on its performance. These systems cost-effectively generate high yields of lab grade, pesticide-free product irrespective of local climate conditions.

Fundamentally, Seedo is a grow fridge. The design of it is for smart usage of space. It features intelligent automated hydroponic system technology. Seedo grow machines deliver maximum yields using minimum living space and energy. Seedo also comes with an app to help one monitor everything with minimal effort on their part.

Last week, Seedo announced a strategic partnership with OutForm, a future retail company to develop Seedo's retail branding strategy in the United States. and to optimize Seedo's present U.S. distribution channels and supply chain.

Seedo Chief Executive Officer, Zohar Levy, said, "We are entering a new era of home growing where demand for complete automated grow systems will only continue to increase. The U.S. is poised to embrace this new world of agritech, and we're thrilled to partner with OutForm to increase Seedo's exposure and introduce our automated home grow device to mainstream retailers and consumers as we expand our extensive community of customers."

                   

Seedo Corp. (SEDO), closed Tuesday's trading session at $2.40, up 3.67%, on 12,347 volume with 20 trades. The average volume for the last 3 months is 50,629 and the stock's 52-week low/high is $0.27/$5.00.

chart

Blue Eagle Lithium, Inc. (BEAG)

All Penny Stocks, Simply Wall St, Nasdaq, Financial Buzz, Stockhouse, OTC Markets, Last10k, and Market Screener reported earlier on Blue Eagle Lithium, Inc. (BEAG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A lithium exploration company, Blue Eagle Lithium, Inc. engages in identifying, evaluating, and developing early-stage lithium exploration opportunities in North America. The design of the Company’s growth strategy is to maximize shareholder value through a singular emphasis on lithium exploration and development in secure and stable North American regions. OTCQB-listed, Blue Eagle Lithium has its corporate headquarters in Henderson, Nevada.

The Company’s initial property is in Railroad Valley, Nevada, a highly prospective green-fields Petro-Lithium brine target region that features numerous similarities to the nearby Clayton Valley and which Blue Eagle Lithium believes warrants an extensive exploration program. It has a 100 percent Working Interest (WI) in 276 placer claims in Railroad Valley.

The Company’s Railroad Property warrants surface and shallow drilling evaluation for possible surface-mineable lithium-rich units based on different sources of geological data. The main exploration target within the Railroad Property would be more recent playa sediments, mostly within 2,000 feet (610 meters) of the valley’s surface. Railroad Valley is an isolated sedimentary basin. It exhibits all the important attributes of a large commercial petro-lithium discovery.

Yesterday, Blue Eagle Lithium announced that it has engaged Rangefront Geological to begin an extended soil sampling program covering its original 4,000 acre land position in Railroad Valley and its recently acquired acreage, the latter of which has received only limited evaluations to date. Rangefront Geological is a premier geological contracting and consulting company based locally out of Elko, Nevada. A crew from Rangefront will be mobilized to start work on the properties with the goal to gather up to 250 near surface clay and brine samples.

In addition, Blue Eagle Lithium announced it further extended its land package through the exercise of an option agreement clause. This extends its land holdings by an additional 520 acres (26 Mineral Claims). In total, the land package now held by Blue Eagle Lithium is 5,520 acres (276 claims, approximately 2,223 Hectares).

Blue Eagle Lithium, Inc. (BEAG), closed Tuesday's trading session at $1.3205, up 3.16%, on 142,417 volume with 180 trades. The average volume for the last 3 months is 25,940 and the stock's 52-week low/high is $0.25/$3.50.

chart

Northern Minerals & Exploration Ltd. (NMEX)

Club Penny Stocks Network, OTPicks, OTCBB Journal, Orbit Stocks, Northern Miner, SmallCapVoice, Proactive Investors, Penny Stock Tweets, Mining Feeds, MarketWatch, TopPennyStockMovers, First Penny Picks, InvestorsHub, Marketwired, Junior Mining Network, OTC Markets, Wallet Investor, 4-Traders, and Stockhouse reported earlier on Northern Minerals & Exploration Ltd. (NMEX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Northern Minerals & Exploration Ltd. is a natural resource company listed on the OTC Markets. Its focus is on oil and gas exploration & production in Texas, gold & silver exploration in Nevada, and hotel & resort development in Mexico. The Company previously went by the name Punchline Resources Ltd. It changed its corporate name to Northern Minerals & Exploration Ltd. in August of 2013. Northern Minerals & Exploration is based in Salt Lake City, Utah.

In 2017, Northern entered into a Letter of Intent (LOI) with a private Mexican entity to work together and conduct due diligence for participating in projects in Mexico with an initial emphasis on a property in the State of Quintana Roo. This Property is a part of the Riviera Maya. It is near the earlier discovered Ichkabal Mayan ruins. It is positioned on the Caribbean coast of the Yucatan Peninsula. The Company considers the Property to have considerable potential for resort development.

Northern Minerals & Exploration has established a Mexican Subsidiary - Enmex Operaciones for Real Estate Development Projects in Mexico. In addition, the Company created Kathis Energy LLC, as a wholly-owned subsidiary. Kathis is establishing oil and gas operations in west and south Texas.

Furthermore, Northern Minerals & Exploration also recently announced the signing of a Memorandum of Understanding (MOU) with Labrador Capital SAPI De CV on March 8, 2019. This is the initial step toward entering into a Joint Venture (JV) Agreement for pursuing real estate development opportunities in the Puerto Morelos region of the Yucatan Peninsula of Mexico with Labrador.

Labrador has successfully developed real estate projects in Mexico, particularly in Puerto Morelos, considered to be the Mexican Riviera in the State of Quintana Roo. Labrador is a significant shareholder of Northern Minerals & Exploration and its President is Mr. Victor Miranda, who also serves as the Company’s Chief Financial Officer. 

Northern Minerals & Exploration Ltd. (NMEX), closed Tuesday's trading session at $0.05, up 46.63%, on 13,000 volume with 2 trades. The average volume for the last 3 months is 24,876 and the stock's 52-week low/high is $0.0155/$0.1199.

chart

Galaxy Gaming, Inc. (GLXZ)

Penny Stock Tweets, InvestorsHub, MarketWatch, FeedBlitz, Dividend Investor, StockInvest, Red Chip, SmallCapVoice, Marketbeat, Seeking Alpha, The Street, Taglich Brothers, The Green Baron, YCharts, Barchart, Stock Profile, Investors Hangout, MicroSmallCap and Equities reported previously on Galaxy Gaming, Inc. (GLXZ), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Galaxy Gaming, Inc. is the world's largest independent developer, manufacturer, and distributor of casino table games and enhanced systems. It develops, manufactures, and distributes innovative proprietary table games, state-of-the-art electronic wagering platforms, and enhanced bonusing systems to land-based, riverboat, cruise ships, and online casinos worldwide. OTCQB-listed, Galaxy Gaming has its corporate headquarters in Las Vegas, Nevada.

The Company has an installed base of its products on thousands of gaming tables located in hundreds of casinos. Galaxy Gaming sells its products primarily through its internal sales force, to casinos across North America, the Caribbean, the British Isles, Europe, and Africa. In addition, Galaxy Gaming sells its products to cruise ships and internet gaming sites globally.

Furthermore, by way of its iGaming partner, Progressive Games Marketing Ltd., Galaxy Gaming licenses its proprietary table games to the online gaming industry. The Company’s games can be played online at FeelTheRush.com.   

Galaxy Gaming is the exclusive provider of SpectrumVision. This is a proprietary technology used to detect invisible markings on playing cards. Moreover, Galaxy is expanding its international reach via its partnership with WPT Enterprises, Inc.  WPT Enterprises is the owner of the World Poker Tour. 

Galaxy Gaming has acquired a portfolio of intellectual property (IP) developed by students participating in UNLV’s Center for Gaming Innovation. The portfolio consists of an array of table games and table-game apparatus that was further prepared for commercialization and sold to Galaxy Gaming by Big Bet Gaming, LLC.

Mr. Todd P. Cravens is the President and Chief Executive Officer (CEO) of Galaxy Gaming. He was most recently the CEO of the Americas for TCS John Huxley for the last three and a half years. Mr. Cravens has greater than 25 years of experience in the amusement and gaming industries. This includes executive positions at American Gaming Systems (AGS) and Betson Enterprise. He is well respected in the gaming industry for his team-building skills.

Galaxy Gaming, Inc. (GLXZ), closed Tuesday's trading session at $1.80, up 0.56%, on 2,669 volume with 3 trades. The average volume for the last 3 months is 20,851 and the stock's 52-week low/high is $1.05/$2.20.

chart

Newgioco Group, Inc. (NWGI)

Simply Wall St, Investor Place, Wallmine, MarketWatch, Investors Hangout, Barchart, Wallet Investor, The Street, OTC Markets, Cantech Letter, Stockhouse, InvestorsHub, TradingView, and last10K reported earlier on Newgioco Group, Inc. (NWGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Newgioco Group, Inc. is a betting software technology business. The Company provides regulated leisure lottery and gaming products and services by way of licensed subsidiaries based in Europe. Newgioco has fully licensed online and land-based gaming operations in Italy and Austria. Newgioco Group, together with its wholly-owned subsidiaries, is a fully-licensed and integrated gaming software technology enterprise. OTCQB-listed, Newgioco Group is based in Toronto, Ontario.

The Company acquired Multigioco Srl, a licensed gaming operator headquartered in Rome, Italy. Newgioco’s plan is to aggressively pursue attractively priced, fragmented, and profitable gaming operators in Italy. Its goal is to become a top-tier gaming operator over a five-year investment time horizon.

Newgioco Group provides its clients a comprehensive set of leisure gaming products and services. These include sports betting, virtual sports, online casino, poker, bingo, lottery, as well as interactive games and slots. The Company conducts its business chielfy through retail neighborhood betting shops and an internet-based gambling and sports betting software platform under the registered brand Newgioco, via its licensed website www.newgioco.it in Italy. Additionally, Newgioco offers a unique betting platform (www.odissea.at) providing B2B (Business-to-Business) and B2C (Business-to-Consumer) bet processing.

Newgioco presently reaches online user accounts, web cafes, and land-based gaming locations through three core distribution channels. These channels are Sporting Stores (agencies or arcades), Sporting Points (corners), and Virtual Reload Points (shop, web cafes or websites).

Newgioco Group has launched CHATBOT, its initial phase of Artificial Intelligence (AI) technology incorporated into its innovative ELYS betting platform by Odissea. CHATBOT is an inventive AI betting technology using customized pattern recognition and machine-learning algorithms to determine the relevant features of customer interactions and to develop a complete customer betting profile.

Recently, Newgioco Group announced that it completed the acquisition of Virtual Generation Limited (VG), a foremost developer of virtual gaming software, together with Naos Holding Limited, a private holding company, effective January 30, 2019 for roughly $4.5 million in a combination of cash and stock. Newgioco’s plan is to use the VG platform for racing, keno, American Roulette and other casino games, within its ELYS platform. Concurrently, the Company plans to introduce the VG product line into the regulated Italian market, using Newgioco's existing Italian ADM platform certification.

Newgioco Group, Inc. (NWGI), closed Tuesday's trading session at $0.25, down 4.95%, on 48,958 volume with 16 trades. The average volume for the last 3 months is 81,384 and the stock's 52-week low/high is $0.23/$0.87.

chart

Rise Gold Corp. (RYES)

StockChase, Junior Mining Network, Metals News, MarketWatch, Marketwired, 4-Traders, OTC Markets, Stockhouse, Epstein Research, GuruFocus, Canadian Insider, Streetwise Reports, Wallet Investor, and Market Screener reported earlier on Rise Gold Corp. (RYES),  and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.  

Rise Gold Corp. is an exploration-stage mining company based in Vancouver, British Columbia. Its main asset is the historic past producing Idaho-Maryland (I-M) Gold Mine in California. The Idaho-Maryland Mine was a significant past producer, yielding 2.4M oz of gold. Rise Gold’s shares trade on the OTC Markets Group’s OTCQB.

The Idaho-Maryland Gold Mine property is fully-owned by Rise Gold. This includes surface and mineral rights. Rise Gold owns all the mineral rights. This Mine is near Grass Valley, California.

The Idaho-Maryland Gold Mine produced a total of 2,414,000 oz gold with an average mill head grade of 0.50oz/ton (about 17g/t). The Mine was producing up to 129,000 oz gold per year before being forced to shut down by the U.S. government in 1942. During WW II the U.S. War effort wanted to shut down precious metals excavation and shift the national mining workforce from gold to copper production.

Rise Gold announced in 2018 that it completed the purchase of 82 acres of fee-simple land (Mill Site Property) contiguous to the historic New Brunswick mine shaft. Total payments to acquire an undivided 100 percent interest in the Mill Site Property were US$1,900,000. Rise Gold invested US$3,900,000 for the purchase of private land in Nevada County, California. It bought the Mill Site Property to support the exploration and future development of the Idaho-Maryland (I-M) Gold Project.

This past December, Rise Gold announced additional assay results from continuing diamond core drilling at the Idaho-Maryland (I-M) Gold Project. The exploration drill program at the I-M Gold Project continues to be successful. Recent drilling tested a number of new targets that produced the highest-grade gold intercept to-date.

The first drill hole in 52 Vein area assays 149.3 gpt gold over 6.8 m. It confirms the 52 Vein area as a significant exploration target. As of December 13, 2018, drilling of the Idaho #1 Vein target was currently in-progress.

Rise Gold Corp. (RYES), closed Tuesday's trading session at $0.0544, up 7.30%, on 58,900 volume with 3 trades. The average volume for the last 3 months is 118,126 and the stock's 52-week low/high is $0.0351/$0.105.

chart

Indoor Harvest  Corp. (INQD)

Orbit Stocks, Awesome Penny Stocks, CFN Media Group, InvestorsHub, Stockhouse, Cannabis Financial Network News, Massive Stock Profits, Make Penny Stocks Great Again, SmallCapVoice, MarketWatch, Microcap Daily, Fast Money Alerts, Stock Shock and Awe, OTPicks, Penny Stock General, and PennyPickAlerts reported earlier on Indoor Harvest  Corp. (INQD), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, Indoor Harvest  Corp. is a developer of personalized cannabis medicines. In addition, the Company is a provider of advanced cultivation technology, methods, and processes. Indoor Harvest provides the cannabis industry production platforms for Building Integrated Agriculture (BIA) production. Established in 2011, the Company has its corporate headquarters in Houston, Texas. It is now moving its base of operations and focus to the Boston, Massachusetts area to leverage what it believes to be an attractive environment for cannabis companies since Massachusetts has legalized medicinal and recreational cannabis.

Indoor Harvest has transitioned into a producer of cannabis for research and pharmaceutical development. The Company’s patent pending aeroponic methods allow for the production of chemically consistent, contaminate free cannabis, economically at scale.

Indoor Harvest is a pending applicant to produce cannabis under the Texas Compassionate Use Program and is seeking additional licenses in the State of Massachusetts. The Company is moving its operational emphasis to Boston, Massachusetts.

Indoor Harvest has entered into a non-binding Memorandum of Understanding (MOU) to explore the creation of a joint venture (JV) partnership with Cannabis Community Care and Research Network (C3RN) and Integrated Genetics & BioPharma Research (IGBR). Indoor Harvest’s plan is to work with C3RN and IGBR to develop a plan to acquire or lease properties and pursue research and development (R&D) initiatives. Additionally, the Company expects to have the ability to offer contract research services and product development services to the cannabis community at large.

The proposed JV will work to identify and publish best practices for cultivation of cannabis via rigorous R&D. Moreover, the JV group aims to provide data and develop partner-specific research studies and goals with academic and other research institutions.

Indoor Harvest’s Management is working to deploy its integrated aeroponic technology platform, on its own and with partners in the Boston area, to demonstrate and highlight the Company’s belief in the technology’s ability to considerably decrease operating costs while boosting yield and quality.

Indoor Harvest  Corp. (INQD), closed Tuesday's trading session at $0.02, up 25.00%, on 164,107 volume with 14 trades. The average volume for the last 3 months is 258,760 and the stock's 52-week low/high is $0.012/$0.288.

chart

Dyadic International, Inc. (DYAI)

Stockflare, Zacks, Street Insider, Stockopedia, MarketWatch, Morningstar, Corporate Connect, Equity Clock, GuruFocus, Proactive Investors, Investors Hub, MicroCapDaily, YCharts, Journal Transcript, Capital Cube, Stockhouse, and Market Screener reported earlier on Dyadic International, Inc. (DYAI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dyadic International, Inc. is a global biotechnology company listed on the OTC Markets’ OTCQX. Its emphasis is on further improving and applying its proprietary C1 gene expression platform to speed up the development and lessen the cost of biologic vaccines and drugs at flexible commercial scales. Dyadic International has a foreign subsidiary, Dyadic Nederland, BV, which maintains a small satellite office in Wageningen, the Netherlands. Dyadic International has its corporate office in Jupiter, Florida.

Dyadic International has developed a method for producing commercial quantities of enzymes and other proteins needed for the production of industrial enzymes. The Company has successfully licensed this technology to third parties including Abengoa Bioenergy, BASF, Codexis and others.

The foundation of the technology is on the Myceliophthora thermophila fungus that Dyadic named C1. The C1 technology is a strong and versatile fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.

The Company’s C1 Expression System is an optimized and industrially proven system. It turns genes into a wide array of valuable products. The C1 Technology Platform helps to overcome some of the inadequacies of existing expression technologies used for gene discovery, product development and commercialization. Dyadic is seeking research collaborations, government funding, partners, and sub-licensees in which to apply the C1 platform in the vaccine, antibody, biosimilar and biobetters industries.

Last month, Dyadic International announced it was named to the 2019 OTCQX® Best 50. This is a ranking of top performing companies traded on the OTCQX Best Market in 2018. The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market. The ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the prior calendar year. Companies in the 2019 OTCQX Best 50 were ranked based on their performance last year.

Dyadic International, Inc. (DYAI), closed Tuesday's trading session at $5.66, up 3.95%, on 157,194 volume with 784 trades. The average volume for the last 3 months is 97,001 and the stock's 52-week low/high is $1.39/$6.3894.

chart

AMMO, Inc. (POWW)

NetworkNewsWire, Savvy Trader Resource, StockaWiki. Infront Analytics, Market Screener, Simply Wall St, MarketWatch, Street Insider, Stockopedia, Wallmine, Capital Cube, Morningstar, Dividend Investor, Wallet Investor, 4-Traders, Business Insider, The Street, InvestorsHub, Barchart, Stockhouse, Euro Investor, GuruFocus, Stockwatch, and TradingView reported on AMMO, Inc. (POWW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AMMO, Inc. is a technology leader and a premier American ammunitions manufacturer. The Company designs and manufactures products for an array of aptitudes. These include law enforcement, military, hunting, sport shooting and self-defense. Established in 2016, AMMO has its head office in Scottsdale, Arizona. The Company also has a manufacturing facility in Payson, Arizona.

AMMO promotes branded munitions. This includes its patented STREAK™ Visual Ammunition, the Jesse James line of munitions and accessories, /stelTH/ subsonic munitions, TAC-P™ Tactical Precision Defense munitions, and OPS (One Precise Shot) a lead-free frangible tactical line of munitions for self-defense.

The Company’s STREAK is a next- generation “Non-Flammable” visual “tracer style” ammunition that is a non-incendiary round, safe for indoor and outdoor use. The American Hunter and Safari Series OSK Line will encompass the whole range of game hunting. Professional hunter and Sports Channel host, Mr. Jeff Rann designed the line.

Moreover, AMMO has worked with well-known motorcycle/firearm designer and builder Mr. Jesse James to create the Jesse James line of branded bullets. Furthermore, the Company’s OPS™ rounds were developed to meet a broad array of demanding engagement scenarios usually experienced by law enforcement personnel in the line of duty.

The design of AMMO’s STELTH™ line was from the ground up with decibel drop and cleanliness in mind. It is a fusion of proprietary HyperClean® technology, precision standards, and foremost suppressor manufacturer collaboration.

Also, AMMO launched its new line of branded precision defense ammunition, TAC-P™ or Tactical Precision, at the 2019 SHOT Show in Las Vegas, Nevada on January 22, 2019. The new line of products is scheduled to move into full production over the next few months.

TAC-P™ is the first of its type ‘made in America’ portfolio to include a high-performing, match grade capability in a solid copper boat tail and API configurations. In addition, the TAC-P™ line is available with AMMO’s patented one-way luminescent or O.W.L. Technology™, or as it is recognized in the commercial markets, STREAK™ Visual Ammunition.

AMMO, Inc. (POWW), closed Tuesday's trading session at $2.02, down 8.18%, on 9,900 volume with 11 trades. The average volume for the last 3 months is 10,298 and the stock's 52-week low/high is $1.029/$6.09.

chart

The QualityStocks Company Corner

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. The interview can be heard at http://nnw.fm/94zqW. Also today, NetworkNewsWire released a report on the company detailing how INMB is ‘One to Watch.’ To view the full article, visit: http://nnw.fm/2XXh6.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.73, up 5.09%, on 12,027 volume with 93 trades. The average volume for the last 3 months is 18,373 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands (CSE:GGB) (OTC:GGBXF) was highlighted today in a publication from FN Media Group, examining how cannabis’ mainstream appeal continues to grow, Wall Street has taken notice of the marijuana industry’s potential for quintupling, at minimum, in worldwide cannabis sales through 2029.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $2.4884, up 0.34%, on 311,350 volume with 499 trades. The average volume for the last 3 months is 258,707 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has recently seen spectacular improvements in the effectiveness of cannabinoids thanks to its proprietary chemical delivery treatment.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.9012, up 5.44%, on 96,360 volume with 65 trades. The average volume for the last 3 months is 104,778 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) this morning announced that Free People, a bohemian lifestyle and fashion brand, is now offering the company’s CBD-infused botanical wellness products for purchase online. Free People is part of a portfolio of global consumer brands called “URBN” which also includes Urban Outfitters, Anthropologie, BHLDN, Terrain and the Vetri Family. The Wildflower CBD+ Cool Stick, Wildflower CBD+ Healing Stick, Wildflower CBD+ Vanilla Soap and Wildflower CBD+ Lavender Soap are now available under the Beauty & Wellness Collection on FreePeople.com. To view the full press release, visit: http://nnw.fm/gPf5W.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.4729, up 1.85%, on 6,558 volume with 13 trades. The average volume for the last 3 months is 24,194 and the stock's 52-week low/high is $0.009/$1.129.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. One of the biggest issues that has stood in the way of medical marijuana patients and healthcare professionals has been the challenge of how to determine the precise dosage to be administered in order to attain the required therapeutic effects.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.4632, up 0.70%, on 185,303 volume with 50 trades. The average volume for the last 3 months is 230,542 and the stock's 52-week low/high is $0.413/$1.53.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile’s (TSX.V: SIM) (OTCQX: SYATF) flagship device, the UV350, is a push-to-talk over cellular (“PoC”) device designed as an all-in-one in-vehicle data platform for commercial fleets (http://nnw.fm/fXEn5). To view the full article, visit: http://nnw.fm/4HvyA.

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed the day's trading session at $0.35584, up 1.81%, on 24,030 volume with 8 tardes. The average volume for the last 3 months is 64,315 and the stock's 52-week low/high is $0.254/$0.446.

Recent News

chart

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Growth in demand for batteries is pushing up nickel production and economic change in Indonesia. Pacific Rim Cobalt Corporation (OTCQB: PCRCF) (CSE: BOLT) (PCRCF Profile) is making the most of Indonesian nickel through an aggressive exploration and development program there. VALE S.A. (NYSE: VALE), the world’s leading nickel producer, is also invested in Indonesia.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed the day's trading session at $0.1149, up 7.08%, on 29,084 volume with 13 trades. The average volume for the last 3 months is 23,652 and the stock's 52-week low/high is $0.0701/$0.378.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, recently entered an agreement to distribute its SofPulse, an easy-to-place, noninvasive device delivering pulsed electromagnetic frequencies to enhance postsurgical recovery, to Veterans Administration facilities and Department of Defense health care facilities. To view the full article, visit: http://nnw.fm/Z0zAx.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed the day's trading session at $0.011, up 5.77%, on 1,521,308 volume with 35 trades. The average volume for the last 3 months is 2,670,962 and the stock's 52-week low/high is $0.009/$0.066.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Canada is drawing closer to the legalization of edibles and derivative products, which is expected to occur this fall. As noted by Green Entrepreneur, edibles are expected to increase to 12-14 percent of the total cannabis market in Canada and the U.S. by 2022 (http://nnw.fm/J83cW). The pending rise of the edibles sector is good news for companies such as Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) that are positioning themselves to capture this further growth opportunity.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed the day's trading session at $7.25, off by 1.89%, on 643,623 volume with 3,076 trades. The average volume for the last 3 months is 1,090,764 and the stock's 52-week low/high is $2.97/$8.44.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy company, recently announced that it has retained pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://nnw.fm/4arQW). To view the full article, visit: http://nnw.fm/NJy28.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.38, off by 4.83%, on 9,885 volume with 34 trades. The average volume for the last 3 months is 49,462 and the stock's 52-week low/high is $0.95/$10.2802.

Recent News

chart

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Consumer health care company Geyser Brands Inc. (TSX.V: GYSR) recently announced its entry into a definitive agreement for the acquisition of Solace Management Group Inc., a private corporation existing under the laws of British Columbia.

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.64, off by 1.54%, on 12,000 volume with 4 trades. The average volume for the last 3 months is 8,719 and the stock's 52-week low/high is $0.55/$0.85.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech (OTCQB: ETST), a Florida-based biotech company, has positioned itself for success through its focus on strategic partnerships and becoming an international leader in the CBD sector. To view the full article, visit: http://nnw.fm/BW9Tx.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.58, off by 1.58%, on 16,139 volume with 21 trades. The average volume for the last 3 months is 36,792 and the stock's 52-week low/high is $0.30/$2.45.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTCQB: SGSI), a leading provider of telecommunications engineering and infrastructure services and solutions, provides services directly to carriers, aggregators, utilities, enterprise operations, project management organizations (“PMOs”) and original equipment manufacturer (“OEM”) clientele. To view the full article, visit: http://nnw.fm/Vc6Xd.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.135, off by 6.90%, on 6,571 volume with 5 trades. The average volume for the last 3 months is 58,427 and the stock's 52-week low/high is $0.071/$2.59.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

Recent financial results released by VPR Brands LP (OTC: VPRB) show that the multi-brand developer and marketer of nicotine and cannabis products has what it takes to scale up successfully. Revenues for the first quarter of 2019 are up, year-over-year, approximately 31 percent, continuing the trend from the year before, when the top line for 2018 climbed to $4,613,300 and marked a 28 percent increase over 2017 revenues of $3,610,379. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. One of the biggest issues that has stood in the way of medical marijuana patients and healthcare professionals has been the challenge of how to determine the precise dosage to be administered in order to attain the required therapeutic effects. Additionally, it has been hard to find cannabis products whose potency is uniform in order to trigger repeatable outcomes in patients.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed the day's trading session at $0.06, off by 11.29%, on 51,985 volume with 8 trades. The average volume for the last 3 months is 75,532 and the stock's 52-week low/high is $0.026/$0.1397.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.